What is the 13F Pro Quality Score for BIO?

13F Pro ranks BIO-RAD LABORATORIES, INC. (BIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BIO's current score at https://13fpro.ai/company/BIO (free sign-up required for the full ranking).

Where does 13F Pro source BIO data?

All BIO-RAD LABORATORIES, INC. fundamentals and ownership data come directly from SEC EDGAR. BIO-RAD LABORATORIES, INC. files with the SEC under CIK 12208. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BIO in?

BIO-RAD LABORATORIES, INC. (BIO) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is BIO research updated on 13F Pro?

BIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIO-RAD LABORATORIES, INC.(BIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 12208 BIO stock profile & AI dashboard →

13F Pro Quality Score

48.9/100

Rank #1,689 of 2,961 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

26.0/100

Profitability

48.4/100

Balance Sheet

54.3/100

Earnings Quality

73.0/100

Free Cash Flow

62.9/100

Institutional Flow

13.4/100

Revenue Scale

67.1/100

Dilution Risk

38.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BIO Scores 49/100

exact factor attribution · 2026-09-11

BIO's composite is driven by scale and earnings quality, held back by revenue growth and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+2.6 pts

67th pct

Earnings quality

+2.3 pts

73th pct

Free cash flow

+1.9 pts

63th pct

Capital efficiency

+0.4 pts

54th pct

Profitability

-0.2 pts

48th pct

Shareholder dilution

-0.6 pts

38th pct

Earnings growth

-0.9 pts

33th pct

Institutional flow

-1.8 pts

13th pct

Revenue growth

-4.8 pts

26th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BIO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BIO-RAD LABORATORIES, INC. (BIO), a Technology sector company. 13F Pro's AI-powered ranking engine scores BIO at 48.9/100 on a 32-signal composite quality model, placing it at rank #1,689 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (13.4) and revenue growth (26.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIO-RAD LABORATORIES, INC. reports quarterly revenue of $651.0M, net income of $371.4M, free cash flow of $66.7M. Top institutional holders of BIO by reported 13-F value include First Eagle Investment Management, BlackRock, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. BIO trades on the NYSE exchange and files with the SEC under CIK 12208. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-RAD LABORATORIES, INC. directly from SEC EDGAR. BIO-RAD LABORATORIES, INC.'s 13F Pro composite quality score has ranged between 33 and 80 since 2021, currently 48.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$651.0M

Net Income

Q2 2026

$371.4M

Free Cash Flow

Q2 2026

$66.7M

ROIC

Q2 2026

3.5%

D/E Ratio

Q2 2026

0.17

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+0.7% YoY

$2.58BFY 2025

FY22 $2.80BFY23 $2.67BFY24 $2.57BFY25 $2.58B

Net Income

+141.2% YoY

$759.9MFY 2025

FY22 $-3.63BFY23 $-637.3MFY24 $-1.84BFY25 $759.9M

Operating Income

-82.5% YoY

$47.2MFY 2025

FY22 $482.6MFY23 $337.8MFY24 $269.0MFY25 $47.2M

EPS (Diluted)

+142.6% YoY

$27.85FY 2025

FY22 $-121.79FY23 $-21.82FY24 $-65.36FY25 $27.85

Total Assets

+12.9% YoY

$10.58BFY 2025

FY22 $13.50BFY23 $12.30BFY24 $9.36BFY25 $10.58B

Total Debt

+0.8% YoY

$1.21BFY 2025

FY22 $1.20BFY23 $1.21BFY24 $1.20BFY25 $1.21B

Op. Cash Flow

+16.9% YoY

$532.2MFY 2025

FY22 $194.4MFY23 $374.9MFY24 $455.2MFY25 $532.2M

Free Cash Flow

+29.4% YoY

$374.6MFY 2025

FY22 $81.6MFY23 $218.2MFY24 $289.6MFY25 $374.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.58B +0.7%	$2.57B -3.9%	$2.67B -4.7%	$2.80B -4.1%	$2.92B +14.8%	$2.55B
Net Income	$759.9M +141.2%	$-1.84B -189.4%	$-637.3M +82.4%	$-3.63B -185.3%	$4.25B +11.5%	$3.81B
Operating Income	$47.2M -82.5%	$269.0M -20.4%	$337.8M -30.0%	$482.6M -3.5%	$500.3M +18.8%	$421.3M
EPS (Diluted)	$27.85 +142.6%	$-65.36 -199.5%	$-21.82 +82.1%	$-121.79 -186.5%	$140.83 +11.4%	$126.47
Total Assets	$10.58B +12.9%	$9.36B -23.9%	$12.30B -8.9%	$13.50B -24.0%	$17.78B +37.0%	$12.97B
Total Debt	$1.21B +0.8%	$1.20B -0.8%	$1.21B +1.0%	$1.20B +11291.6%	$10.5M -14.2%	$12.3M
Operating Cash Flow	$532.2M +16.9%	$455.2M +21.4%	$374.9M +92.8%	$194.4M -71.0%	$669.5M +14.4%	$585.0M
Free Cash Flow	$374.6M +29.4%	$289.6M +32.7%	$218.2M +167.4%	$81.6M -84.8%	$535.7M +12.4%	$476.4M

Get alerted when BIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIO-RAD LABORATORIES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BIO

First Eagle Investment Management, LLC
$765.2M2,606,219 sh
BlackRock, Inc.
$498.8M1,698,929 sh
DIMENSIONAL FUND ADVISORS LP
$277.3M944,548 sh
VANGUARD CAPITAL MANAGEMENT LLC
$242.8M826,972 sh
ARIEL INVESTMENTS, LLC
$239.8M816,751 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$239.6M816,198 sh
EARNEST PARTNERS LLC
$170.5M580,752 sh
STATE STREET CORP
$167.9M571,762 sh
BANK OF AMERICA CORP /DE/
$144.0M490,412 sh
Capital World Investors
$135.8M462,457 sh

Fund	Value	Shares
First Eagle Investment Management, LLC	$765.2M	2,606,219
BlackRock, Inc.	$498.8M	1,698,929
DIMENSIONAL FUND ADVISORS LP	$277.3M	944,548
VANGUARD CAPITAL MANAGEMENT LLC	$242.8M	826,972
ARIEL INVESTMENTS, LLC	$239.8M	816,751
VANGUARD PORTFOLIO MANAGEMENT LLC	$239.6M	816,198
EARNEST PARTNERS LLC	$170.5M	580,752
STATE STREET CORP	$167.9M	571,762
BANK OF AMERICA CORP /DE/	$144.0M	490,412
Capital World Investors	$135.8M	462,457

Companies Similar to BIO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

LFUS

LITTELFUSE INC /DE

AI score

Similar quality profile · 13 shared holders

EARNEST PARTNERS LLC ARIEL INVESTMENTS, LLC Boston Trust Walden Corp

VNT

Vontier Corp

AI score

Similar quality profile · 17 shared holders

THOMPSON SIEGEL & WALMSLEY LLC Retirement Systems of Alabama Marathon Asset Management Ltd

QRVO

Qorvo, Inc.

AI score

Similar quality profile · 10 shared holders

MANGROVE PARTNERS IM, LLC ING GROEP NV Point72 Asia (Singapore) Pte. Ltd.

GNRC

GENERAC HOLDINGS INC.

AI score

Similar quality profile · 6 shared holders

ARIEL INVESTMENTS, LLC Capital World Investors Freestone Grove Partners LP

FCN

FTI CONSULTING, INC

AI score

Similar quality profile · 22 shared holders

Mawer Investment Management Ltd.Marathon Asset Management Ltd Retirement Systems of Alabama

TRMB

TRIMBLE INC.

AI score

Similar quality profile · 6 shared holders

Retirement Systems of Alabama FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A.STATE TREASURER STATE OF MICHIGAN

ICFI

ICF International, Inc.

AI score

Similar quality profile · 7 shared holders

Capital Research Global Investors Boston Partners Freestone Grove Partners LP

IPGP

IPG PHOTONICS CORP

AI score

Similar quality profile · 15 shared holders

First Eagle Investment Management, LLC Retirement Systems of Alabama Concentric Capital Strategies, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put BIO on your watchlist

Track score changes the day BIO-RAD LABORATORIES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BIO a good stock to buy?

13F Pro's AI-powered analysis of BIO-RAD LABORATORIES, INC. (BIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIO are available on the BIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BIO is classified as a mid company.

Which hedge funds own BIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIO-RAD LABORATORIES, INC.'s investment landscape.